Pharmanutra S.p.A.

DB:761 Stock Report

Market Cap: €518.8m

Pharmanutra Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Roberto Lacorte

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership0.1%
Management average tenureno data
Board average tenure1.9yrs

Recent management updates

Recent updates

CEO

Roberto Lacorte (56 yo)

no data

Tenure

€1,918,290

Compensation

Mr. Roberto Lacorte serves as Vice Chairman, Managing Director and Vice President of Pharmanutra S.p.A. Between January 1995 and April 1996, Mr. Lacorte carried out military service with the Marines. Betwe...

Board Members

NamePositionTenureCompensationOwnership
Andrea Lacorte
Chairman & Presidentno data€2.19mno data
Roberto Lacorte
Vice Chairmanno data€1.92m0.15%
€ 758.0k
Carlo Volpi
Delegate Advisorno data€1.77m10.58%
€ 54.9m
Germano Tarantino
Scientific Director & Executive Director13.9yrs€586.16kno data
Marida Zaffaroni
Independent Directorno data€41.00kno data
Alessandro Calzolari
Lead Independent Directorno data€41.00kno data
Giovanna Zanotti
Independent Directorno data€41.00kno data
Debora Mazzacherini
Standing Auditorno datano datano data
Michele Giordano
President of Supervisory Board1.9yrsno datano data
Pasquale Giovinazzo
Internal Member of Supervisory Board1.9yrsno datano data

1.9yrs

Average Tenure

56yo

Average Age

Experienced Board: 761's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 02:22
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharmanutra S.p.A. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrea RandoneIntermonte SIM S.p.A.
Giorgio TavoliniIntermonte SIM S.p.A.
Daniele AlibrandiStifel, Equities Research